Identification of Progenitor Cells That Contribute to Heterotopic Skeletogenesis

Lounev, Vitali Y.; Ramachandran, Rageshree; Wosczyna, Michael N.; Yamamoto, Masakazu; Maidment, Andrew D. A.; Shore, Eileen M.; Glaser, David L.; Goldhamer, David J.; Kaplan, Frederick S.
March 2009
Journal of Bone & Joint Surgery, American Volume;Mar2009, Vol. 91-A Issue 3, p652
Academic Journal
Background: Individuals who have fibrodysplasia ossificans progressiva develop an ectopic skeleton because of genetic dysregulation of bone morphogenetic protein (BMP) signaling in the presence of inflammatory triggers. The identity of progenitor cells that contribute to various stages of BMP-induced heterotopic ossification relevant to fibrodysplasia ossificans progressiva and related disorders is unknown. An understanding of the cellular basis of heterotopic ossification will aid in the development of targeted, cell-specific therapies for the treatment and prevention of heterotopic ossification. Methods: We used Cre/loxP lineage tracing methods in the mouse to identify cell lineages that contribute to all stages of heterotopic ossification. Specific cell populations were permanently labeled by crossing lineage-specific Cre mice with the Cre-dependent reporter mice R26R and R26R-EYFP. Two mouse models were used to induce heterotopic ossification: (1) intramuscular injection of BMP2/Matrigel and (2) cardiotoxin-induced skeletal muscle injury in transgenic mice that misexpress BMP4 at the neuromuscular junction. The contribution of labeled cells to fibroproliferative lesions, cartilage, and bone was evaluated histologically by light and fluorescence microscopy. The cell types evaluated as possible progenitors included skeletal muscle stem cells (MyoD-Cre), endothelium and endothelial precursors (Tie2-Cre), and vascular smooth muscle (Smooth Muscle Myosin Heavy Chain-Cre [SMMHC-Cre]). Results: Vascular smooth muscle cells did not contribute to any stage of heterotopic ossification in either mouse model. Despite the osteogenic response of cultured skeletal myoblasts to BMPs, skeletal muscle precursors in vivo contributed minimally to heterotopic ossification (<5%), and this contribution was not increased by cardiotoxin injection, which induces muscle regeneration and mobilizes muscle stem cells. In contrast, cells that expressed the vascular endothelial marker Tie2/Tek at some time in their developmental history contributed robustly to the fibroproliferative, chondrogenic, and osteogenic stages of the evolving heterotopic endochondral anlagen. Importantly, endothelial markers were expressed by cells at all stages of heterotopic ossification. Finally, muscle injury and associated inflammation were sufficient to trigger fibrodysplasia ossificans progressiva-like heterotopic ossification in a setting of chronically stimulated BMP activity. Conclusions: Tie2-expressing progenitor cells, which are endothelial precursors, respond to an inflammatory trigger, differentiate through an endochondral pathway, contribute to every stage of the heterotopic endochondral anlagen, and form heterotopic bone in response to overactive BMP signaling in animal models of fibrodysplasia ossificans progressiva. Thus, the ectopic skeleton is not only supplied by a rich vasculature, but appears to be constructed in part by cells of vascular origin. Further, these data strongly suggest that dysregulation of the BMP signaling pathway and an inflammatory microenvironment are both required for the formation of fibrodysplasia ossificans progressiva-like lesions. Clinical Relevance: These cell lineage tracing studies provide new insight into the cellular pathophysiology of heterotopic ossification. Therapeutic regulation of specific cell lineages involved in BMP-induced heterotopic ossification holds promise for the treatment of fibrodysplasia ossificans progressiva and possibly other more common disorders of heterotopic ossification.


Related Articles

  • Developmental biology: Blood-vessel cells turn to bone.  // Nature;11/25/2010, Vol. 468 Issue 7323, p479 

    The article focuses on research regarding the mutation in the Alk2 gene of patients with fibrodysplasia ossificans progressiva (FOP), which results to the formation of bone in soft tissues and the endothelial cells.

  • Treating inherited disease in the womb.  // New Scientist;3/7/2015, Vol. 225 Issue 3011, p17 

    The article reports on research which was conducted by Sébastien Lacroix-Desmazes and his colleagues at the Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris, France and found that priming mice pups whose mothers were predisposed to hemophilia with clotting...

  • Building bone from blood vessels. Horwitz, Edwin M. // Nature Medicine;Dec2010, Vol. 16 Issue 12, p1373 

    In this article the author discusses the study conducted by D. Medici and colleagues concerning the mesenchymal stem cells (MSCs) source on people with fibrodysplasia ossificans progressiva (FOP). He says that the study provided cues that could be used in cell therapy for treating people who...

  • Functional Modeling of the ACVR1 (R206H) Mutation in FOP. Jay Groppe // Clinical Orthopaedics & Related Research;Sep2007, Vol. 462 Issue 1, p87 

    Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation in the glycine-serine activation domain of ACVR1, a bone morphogenetic protein type I receptor....

  • Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. Deirmengian, Gregory K.; Hebela, Nader M.; O'Connell, Michael; Glaser, David L.; Shore, Eileen M.; Kaplan, Frederick S. // Journal of Bone & Joint Surgery, American Volume;Feb2008, Vol. 90-A Issue 2, p366 

    Background: Fibrodysplasia ossificans progressiva is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic ossification of skeletal muscle and soft connective tissues. The disorder is caused by a recurrent missense mutation...

  • Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. Kaplan, Frederick S.; Zasloff, Michael A.; Kitterman, Joseph A.; Shore, Eileen M.; Hong, Charles C.; Rocke, David M. // Journal of Bone & Joint Surgery, American Volume;Mar2010, Vol. 92-A Issue 3, p686 

    Background: Fibrodysplasia ossificans progressiva, a rare genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification in humans. However, little is known about the lifespan or causes of mortality in these patients. We undertook this study to...

  • Clinical and Genetic Analysis of Fibrodysplasia Ossificans Progressiva: A Case Report and Literature Review. LAKKIREDDY, MAHESHWAR; CHILAKAMARRI, VIJAYKRISHNA; RANGANATH, PRAJNYA; ARORA, ABHISHEK JAGDISHCHANDER; VANAJA, MARIA CELESTINA // Journal of Clinical & Diagnostic Research;Aug2015, Vol. 9 Issue 8, p1 

    Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by congenital malformation of the great toes and disabling heterotopic ossification in specific anatomic locations with a world wide prevalence of 1 in 2 million population. Nearly 90% of patients with FOP are...

  • Alterations in Cerebrospinal Fluid Proteins in a Presymptomatic Primary Glioma Model. Whitin, John C.; Taichang Jang; Merchant, Milton; Yu, Tom T-S.; Lau, Kenneth; Recht, Benjamin; Cohen, Harvey J.; Recht, Lawrence // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Background: Understanding the early relationship between brain tumor cells and their environment could lead to more sensitive biomarkers and new therapeutic strategies. We have been using a rodent model of neurocarcinogenesis in which all animals develop brain tumors by six months of age to...

  • Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors. Galietta, Luis // Pediatric Drugs;2013, Vol. 15 Issue 5, p393 

    Cystic fibrosis (CF), a severe genetic disease, is caused by mutations that alter the structure and function of CFTR, a plasma membrane channel permeable to chloride and bicarbonate. Defective anion transport in CF irreversibly damages the lungs, pancreas, liver, and other organs. CF mutations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics